Quark Pharmaceuticals is a Fremont, California-based developer of RNAi-based therapeutics focused on siRNA drugs. The company closed a $10M financing round and will use the proceeds to advance its RNAi drug pipeline. Its pipeline is being evaluated in five clinical trials and is led by PF-04523655, which is in two Phase II trials for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Quark is also evaluating QPI-1002, a systemically administered siRNA whose Phase I enrollment is complete and for which Phase II studies are planned to start shortly. The company operates R&D facilities in Boulder, Colorado and Ness-Ziona, Israel.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2010